Nevertheless, targeting the CLDN10B promoter with VP160 and TET1 in the dCas9 system not only demethylated and reactivated CLDN10B but also restored its tumor-suppressive function in a wound healing assay. This evidence concerns the gene TET1 and neoplasm.